It’s only fair to share… Sebetralstat, KVD 900 CAS 1933514-13-6 491.5 g/mol O5ZD2TU2B7 FDA 7/3/2025, Ekterly, To treat acute attacks of hereditary angioedema N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Sebetralstat, sold under the brand name Ekterly, is a medication used for the treatment of hereditary angioedema.[1] Sebetralstat is a plasma kallikrein inhibitor.[1] Sebetralstat was approved for medical use in the United States in July 2025.[1][2] SYN https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00921 aReagents …